(Q54257317)

26 May 2018

title

Recent developments in viral hepatitis. (English)

1 reference

26 May 2018

author name string

L S Friedman

series ordinal

1

1 reference

26 May 2018

J L Dienstag

series ordinal

2

1 reference

26 May 2018

publication date

1 June 1986

1 reference

26 May 2018

published in

Disease-A-Month

1 reference

26 May 2018

volume

32

1 reference

26 May 2018

issue

6

1 reference

26 May 2018

page(s)

313-385

1 reference

26 May 2018

A "NEW" ANTIGEN IN LEUKEMIA SERA

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2886%2980012-8

Hepatitis A: detection by immune electron microscopy of a viruslike antigen associated with acute illness.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2886%2980012-8

Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2886%2980012-8

The hepadna viruses of animals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2886%2980012-8

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2886%2980012-8

Molecular cloning and characterization of hepatitis A virus cDNA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2886%2980012-8

Serologic investigation of an outbreak of hepatitis A in a rural day-care center

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2886%2980012-8

The Antibody Response Following Hepatitis A Infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2886%2980012-8

Use of IgM-hepatitis A antibody testing. Investigating a common-source, food borne outbreak

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2886%2980012-8

Distribution of Antibody to Hepatitis A Antigen in Urban Adult Populations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2886%2980012-8

Sexual transmission of hepatitis A in homosexual men: incidence and mechanism.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2886%2980012-8

Viral Hepatitis Associated With Day-care Centers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2886%2980012-8

Transmission of Hepatitis A by Transfusion of Blood Products

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2886%2980012-8

Etiology of sporadic hepatitis B surface antigen-negative hepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2886%2980012-8

Relationship between Prevalence of Antibody to Hepatitis A Antigen and Age: A Cohort Effect?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2886%2980012-8

Faecal shedding of hepatitis-A antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2886%2980012-8

Guidelines for the Care of Patients Hospitalized with Viral Hepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2886%2980012-8

Infectious hepatitis. Studies on the effect of gamma globulin and on the incidence of inapparent infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2886%2980012-8

Effect of Human Immune Serum Globulin on Infectivity of Hepatitis A Virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2886%2980012-8

Purification and biophysical characterization of hepatitis B antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2886%2980012-8

Hepatitis B e antigen and infectivity of hepatitis B virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2886%2980012-8

Hepatitis B e antigen and antibody measured by radioimmunoassay in acute hepatitis B surface antigen-positive hepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2886%2980012-8

7 January 2021

The hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2886%2980012-8

Viral hepatitis, type B. Studies on natural history and prevention re-examined

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2886%2980012-8

Type B hepatitis after transfusion with blood containing antibody to hepatitis B core antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2886%2980012-8

Serodiagnosis of recent hepatitis B infection by IgM class anti-HBc

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2886%2980012-8

The significance of IgM antibodies to hepatitis B core antigen in hepatitis B carriers and hepatitis B-associated chronic liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2886%2980012-8

Viral hepatitis, type B, DNA polymerase activity and antibody to hepatitis B core antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2886%2980012-8

Concomitant hepatitis B surface antigen and antibody in thirteen patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2886%2980012-8

Seroconversion from Hepatitis B e Antigen to Antibody in Chronic Type B Hepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2886%2980012-8

Reactivation of chronic hepatitis B virus infection by cancer chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2886%2980012-8

Detection of hepatitis B virus DNA in liver and serum: a direct appraisal of the chronic carrier state

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2886%2980012-8

Relationship of virus dose to incubation time of clinical hepatitis and time of appearance of hepatitis???associated antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2886%2980012-8

Extrahepatic manifestations of viral hepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2886%2980012-8

Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2886%2980012-8

Acute type B hepatitis among HBsAg negative patients detected by anti-HBc IgM

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2886%2980012-8

Experimental transmission of hepatitis B virus by semen and saliva

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2886%2980012-8

Type B hepatitis after needle-stick exposure: prevention with hepatitis B immune globulin. Final report of the Veterans Administration Cooperative Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2886%2980012-8

Accidental hepatitis-B-surface-antigen-positive inoculations. Use of e antigen to estimate infectivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2886%2980012-8

Hepatitis B Immune Globulin as a Prophylactic Measure for Spouses Exposed to Acute Type B Hepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2886%2980012-8

Hepatitis B surface antigen in the serum of infants after deliver from asymptomatic carrier mothers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2886%2980012-8

The e antigen and vertical transmission of hepatitis B surface antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2886%2980012-8

Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2886%2980012-8

Antiviral Treatment of Chronic Hepatitis B Virus Infection. I. Changes in Viral Markers with Interferon Combined with Adenine Arabinoside

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2886%2980012-8

Post-transfusion hepatitis: current perspectives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2886%2980012-8

Prevention of nosocomial viral hepatitis, type B (hepatitis B)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2886%2980012-8

Hepatitis B Immune Globulin — Prevention of Hepatitis from Accidental Exposure among Medical Personnel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2886%2980012-8

Prevention of the HBsAg carrier state in newborn infants of mothers who are chronic carriers of HBsAg and HBeAg by administration of hepatitis-B vaccine and hepatitis-B immunoglobulin. Double-blind randomised placebo-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2886%2980012-8

Viral hepatitis, type B (MS-2-strain). Further observations on natural history and prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2886%2980012-8

Hepatitis B vaccine in medical staff of hemodialysis units: efficacy and subtype cross-protection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2886%2980012-8

Hepatitis B Vaccine in Health Care Personnel: Safety, lmmunogenicity, and Indicators of Efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2886%2980012-8

A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2886%2980012-8

Immune response in neonates to hepatitis B vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2886%2980012-8

Hepatitis B vaccine in patients receiving hemodialysis. Immunogenicity and efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2886%2980012-8

Passive-active immunisation against hepatitis B: immunogenicity studies in adult Americans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2886%2980012-8

Hepatitis B vaccine administered to chronic carriers of hepatitis b surface antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2886%2980012-8

Indications for use of hepatitis B vaccine, based on cost-effectiveness analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2886%2980012-8

Immunofluorescence detection of new antigen-antibody system (delta/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2886%2980012-8

Radioimmunoassay detection of IgM antibodies to the HBV-associated delta (delta) antigen:" clinical significance in delta infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2886%2980012-8

Chronic hepatitis in carriers of hepatitis B surface antigen, with intrahepatic expression of the delta antigen. An active and progressive disease unresponsive to immunosuppressive treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2886%2980012-8

Prevalence of delta antigen/antibody in B-viral-associated hepatocellular carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2886%2980012-8

Infection with delta agent in Sweden: introduction of a new hepatitis agent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2886%2980012-8

Delta infection and liver disease in hemophilic carriers of hepatitis B surface antigen.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2886%2980012-8

Long-incubation post-transfusion hepatitis without serological evidence of exposure to hepatitis-B virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2886%2980012-8

The Chronic Sequelae of Non-A, Non-B Hepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2886%2980012-8

Study of an epidemic of non-A, non-B hepatitis. Possibility of another human hepatitis virus distinct from post-transfusion non-A, non-B type

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2886%2980012-8

Serum alanine aminotransferase of donors in relation to the risk of non-A,non-B hepatitis in recipients: the transfusion-transmitted viruses study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2886%2980012-8

Efficacy of prophylactic gamma-globulin in preventing non-A, non-B post-transfusion hepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2886%2980012-8

Type A viral hepatitis. New developments in an old disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2886%2980012-8

Natural history of the HBsAg carrier

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2886%2980012-8

Prospects for second and third generation hepatitis B vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2886%2980012-8

Delta hepatitis--present status.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2886%2980012-8

Viral hepatitis: clinical aspects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2886%2980012-8

inferred from DOI database lookup

7 January 2021

based on heuristic

Transmission of hepatitis B to chimpanzees by hepatitis B surface antigen-positive saliva and semen

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2886%2980012-8

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0011-5029(86)80012-8

1 reference

26 May 2018

1 reference

26 May 2018